When does a two-stage cartilage procedure become necessary?

Arriving at a two-stage cartilage repair usually means a simpler, one-stage option has already been ruled out — and understanding why helps make sense of what comes next.

The threshold is roughly 2 cm² of focal cartilage loss: approximately the surface area of a 10p coin. Below that, procedures such as microfracture or mosaicplasty may provide adequate fill using the joint's own marrow cells or a bone-and-cartilage plug. Above it, neither technique can supply enough biological material to achieve durable repair. The SUMMIT trial found that for defects of 3 cm² or more, microfracture produced meaningfully worse pain and function scores than cell-based repair at both two and five years — a finding that reflects a structural limitation, not a technical one.

Both ACI and MACI address this by removing the problem of scale from the operating theatre altogether. A small cartilage sample is harvested arthroscopically, sent to a specialist laboratory, and the patient's own chondrocytes are expanded over several weeks before being returned as a far larger cell population ready for implantation.

Suitable candidates share a few key characteristics: a focal defect surrounded by healthy cartilage, a knee without significant diffuse arthritis, and — for MACI specifically — an age range of 18 to 55, which reflects the joint-preserving rather than joint-replacing context these procedures are designed for. Where ACI and MACI diverge is in how those expanded cells are actually delivered at Stage 2, and that difference has real consequences for both the surgery and the recovery.

How ACI and MACI differ in practice

Both procedures share an identical first stage: the arthroscopic biopsy and laboratory expansion outlined above. It is at Stage 2 — the implantation — that ACI and MACI part company, and where the practical differences for both surgeon and patient become apparent.

In first-generation ACI, the expanded cells are re-injected as a liquid suspension directly into the prepared defect, then sealed in place with a thin strip of periosteum — the membrane lining the outer surface of bone — harvested from the shin during the same operation. Second-generation ACI replaced that shin harvest with a sutured collagen cover, which removed the additional incision site but still required careful suturing around the defect margins to create a watertight seal for the cell suspension.

MACI takes a different approach entirely. The cells are seeded uniformly across a preformed porcine Type I/III collagen membrane, which is cut to match the precise shape of the defect and fixed with fibrin glue. There is no periosteal harvest, no second incision on the shin, and no complex suturing around the margins. The practical consequences are measurable: a smaller overall incision, shorter operating time, and — perhaps most clinically meaningful — a substantially lower rate of graft hypertrophy.

In periosteal-cover ACI, overgrowth of the repair tissue was a documented complication that sometimes required a further procedure to trim the excess. The 2005 Bone & Joint RCT reported hypertrophy in 9% of collagen-cover ACI cases against 6% with MACI; the difference in mechanism is what drives that gap. The membrane geometry also gives MACI practical versatility across the medial and lateral femoral condyles, patella, and trochlea, including lesions with open edges that earlier techniques found technically demanding.

In both cases, the 4–8 week laboratory culture period between stages is a fixed feature of the pathway — something patients need to factor into their planning from the outset.

What the clinical evidence shows

The most rigorous direct comparison between ACI and MACI remains a 2005 prospective RCT published in Bone & Joint, which enrolled 91 patients — 44 receiving collagen-cover ACI, 47 receiving MACI — and found statistically equivalent outcomes at one year. Mean Cincinnati knee score improved by 17.6 points in the ACI group against 19.6 in the MACI group (p=0.32), reoperation rates were 9% in each arm, and histological analysis showed comparable proportions of hyaline-like cartilage. The clinical takeaway is that MACI's technical improvements do not come at the cost of a worse clinical result.

The SUMMIT trial adds a complementary signal: rather than comparing ACI directly with MACI, it set MACI against microfracture in patients with defects of 3 cm² or more. MACI produced substantially better KOOS pain and function scores at both two and five years, reinforcing why cell-based repair is recommended once defects cross that size threshold.

For durability, Wang et al. (2024) — representing one of the most comprehensive long-term follow-up datasets currently available — confirmed significant and sustained improvements in patient-reported outcomes at a minimum of ten years post-MACI. Weishorn et al. (2024) adds further weight, reporting low revision rates and consistently high patient satisfaction in a separate long-term cohort.

The realistic success range for MACI runs from 75 to 90% in carefully selected patients; published series for isolated ACI lesions have reported figures as high as 92%. All-cause reoperation sits at approximately 9%; conversion to total knee replacement is around 7.4% at ten to seventeen years — figures worth discussing openly rather than glossing over.

The honest position is that most durability data beyond five years covers each procedure within its own cohort rather than comparing them head to head. That gap is genuine, and it is why clinical assessment of the individual defect remains central to any decision.

Patient selection: who is and isn't a suitable candidate

Suitability for either procedure comes down to a cluster of factors — some fixed, some modifiable — and the reasoning behind each one is worth unpacking before committing to the diagnostic pathway.

The defect must be focal, with healthy cartilage at its margins. Both ACI and MACI depend on the surrounding cartilage acting as a structural boundary for the repair. In diffuse osteoarthritis — where cartilage loss has spread across a wide joint surface — that boundary no longer exists. Without it, there is nowhere to anchor the implant, and the degraded mechanical environment will continue to undermine it. Diffuse OA therefore shifts the conversation toward joint preservation or replacement, not restoration.

The joint must be mechanically sound. Varus or valgus malalignment concentrates load on the compartment being repaired, and proceeding without addressing it substantially raises the risk of early failure. When malalignment is identified, a concurrent or staged osteotomy to redistribute that load is usually considered as part of the overall plan. Objective biomechanical assessment before surgery matters here: loading patterns that are not apparent on a standing X-ray can meaningfully influence both the surgical decision and the rehabilitation programme.

Modifiable risk factors should be tackled beforehand. High BMI, multiple prior knee procedures, and a history of failed marrow-stimulation surgery are all associated with worse outcomes in published series. They are not automatic disqualifiers, but they warrant honest discussion and, where possible, correction.

Age range and defect location. MACI's FDA approval covers adults aged 18–55 — the bracket where the clinical evidence base is strongest; outside those ages, individual clinical grounds determine whether to proceed. The membrane design gives MACI practical flexibility: it can be shaped to treat the medial or lateral femoral condyle, patella, and trochlea, including open-edged lesions where a liquid implant would not hold in place.

Recovery: what the two-stage timeline actually looks like

Once Stage 2 implantation is complete — following the laboratory wait described above — a substantial recovery begins, and it looks nothing like a standard post-surgical timeline.

Full functional recovery takes up to 12 months, and that figure has a biological explanation rather than being an arbitrary instruction. Newly implanted chondrocytes do not mature quickly; the repair tissue needs progressively graduated mechanical loading to stimulate proper extracellular matrix formation and transition from a soft initial repair into durable, weight-bearing cartilage. Applying load too early risks permanent damage to a graft that cannot simply be re-implanted.

The early post-operative weeks focus entirely on protecting the construct: weight-bearing is introduced carefully and increased in controlled phases under physiotherapy supervision. Return to impact activities — running, jumping, physically demanding manual work — is measured in months, not weeks. For patients planning to return to sport, nine to twelve months is the realistic minimum horizon; the exact point depends on the defect site, graft maturation on imaging, and functional testing.

Commitment to a structured twelve-month rehabilitation programme is a genuine patient-selection criterion, and it is worth stating plainly. Candidates who are unable or unwilling to follow supervised physiotherapy across that period carry a meaningfully higher risk of poor outcomes in published series. A thorough pre-operative assessment will explore this directly — not to discourage realistic candidates, but because incomplete rehabilitation is one of the more avoidable causes of graft failure.

ACI and MACI in the UK: availability and next steps

The branded MACI product manufactured by Vericel is not commercially available in the UK. Specialist centres do perform matrix-assisted autologous chondrocyte implantation using equivalent porcine collagen membranes, but access runs through dedicated cartilage units rather than general orthopaedic pathways.

The next evolution from these two-stage techniques is STACi — Single-Treatment ACI — a UK-developed approach that compresses both the biopsy and implantation stages into one procedure. Taylor and Lee described this next-generation method in 2019; long-term outcome data are still accumulating, and STACi should be understood as emerging rather than established. For patients who find a two-stage commitment prohibitive — whether because of the inter-stage wait or the cumulative theatre exposure — it is a route worth raising at specialist consultation.

For patients outside London, access to expert evaluation typically runs through specialist MSK and cartilage centres rather than a standard orthopaedic referral. MSK Doctors operates its Regeneration Hub in Sleaford, Lincolnshire, and the MFO Life Sciences Lab in Grantham — consultant-led sites supporting cartilage assessment and cell-based treatment pathways for patients across the wider non-London catchment, with no GP referral required.

The decision between ACI, a MACI-equivalent technique, or STACi ultimately depends on defect size and location, tolerance for a staged timeline, and what the joint will realistically sustain — none of which can be resolved without direct clinical assessment. A consultant-led evaluation that characterises the defect, identifies modifiable risk factors, and matches the procedure to the patient's anatomy and lifestyle is the essential grounding for any of these choices.

To book a consultant assessment without a GP referral, visit mskdoctors.com.